Yuekang Pharmaceutical (688658.SH) subsidiary YKYY033 injection received approval for clinical trials from the National Medical Products Administration.

Wisdom Finance APP News, Yueshan Pharmaceutical (688658.SH) announced that its subsidiaries Beijing Yueshan Sci-Tech Medicine Technology Co., Ltd. (referred to as "Yueshan Sci-Tech") and Hangzhou Tianlong Pharmaceutical Co., Ltd. (referred to as "Hangzhou Tianlong") recently received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration (NMPA) for "YKYY033 Injection for Use in Scheduled Hip or Knee Replacement Surgery in Adult Patients to Prevent Venous Thromboembolism (VTE)." The company will conduct Phase I clinical trials for this product.